Literature DB >> 29691153

Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.

Khushbu Shah1, Xin Lin1, Sherry F Queener2, Vivian Cody3, Jim Pace3, Aleem Gangjee4.   

Abstract

To combine the potency of trimetrexate (TMQ) or piritrexim (PTX) with the species selectivity of trimethoprim (TMP), target based design was carried out with the X-ray crystal structure of human dihydrofolate reductase (hDHFR) and the homology model of Pneumocystis jirovecii DHFR (pjDHFR). Using variation of amino acids such as Met33/Phe31 (in pjDHFR/hDHFR) that affect the binding of inhibitors due to their distinct positive or negative steric effect at the active binding site of the inhibitor, we designed a series of substituted-pyrrolo[2,3-d]pyrimidines. The best analogs displayed better potency (IC50) than PTX and high selectivity for pjDHFR versus hDHFR, with 4 exhibiting a selectivity for pjDHFR of 24-fold.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DHFR inhibitors; Opportunistic infections; Pneumocystis pneumonia; Pyrrolo[2,3-d]pyrimidines; hDHFR; pjDHFR

Mesh:

Substances:

Year:  2018        PMID: 29691153      PMCID: PMC5967623          DOI: 10.1016/j.bmc.2018.04.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  39 in total

1.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

2.  An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot.

Authors:  Aina E Cohen; Paul J Ellis; Mitchell D Miller; Ashley M Deacon; R Paul Phizackerley
Journal:  J Appl Crystallogr       Date:  2002-12       Impact factor: 3.304

3.  Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.

Authors:  Vivian Cody; Jim Pace; Ojas A Namjoshi; Aleem Gangjee
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-05-27       Impact factor: 1.056

4.  Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis.

Authors:  Aimable Nahimana; Meja Rabodonirina; Jacques Bille; Patrick Francioli; Philippe M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.

Authors:  Dario Sangiolo; Barry Storer; Richard Nash; Lawrence Corey; Chris Davis; Mary Flowers; Robert C Hackman; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Adverse reactions to trimethoprim/sulfamethoxazole in AIDS.

Authors:  Michelle A Floris-Moore; Maria I Amodio-Groton; Michela T Catalano
Journal:  Ann Pharmacother       Date:  2003-12       Impact factor: 3.154

8.  Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.

Authors:  P Nickel; M Schürmann; H Albrecht; R Schindler; K Budde; T Westhoff; J Millward; N Suttorp; P Reinke; D Schürmann
Journal:  Infection       Date:  2014-08-29       Impact factor: 3.553

Review 9.  Cardiotoxicity of antimalarial drugs.

Authors:  Nicholas J White
Journal:  Lancet Infect Dis       Date:  2007-08       Impact factor: 25.071

Review 10.  Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance.

Authors:  Laurence Huang; Kristina Crothers; Chiara Atzori; Thomas Benfield; Robert Miller; Meja Rabodonirina; Jannik Helweg-Larsen
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  3 in total

1.  Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.

Authors:  Khushbu Shah; Sherry Queener; Vivian Cody; Jim Pace; Aleem Gangjee
Journal:  Bioorg Med Chem Lett       Date:  2019-06-04       Impact factor: 2.823

Review 2.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

3.  Novel camphor-based pyrimidine derivatives induced cancer cell death through a ROS-mediated mitochondrial apoptosis pathway.

Authors:  Yan Zhang; Yunyun Wang; Yuxun Zhao; Wen Gu; Yongqiang Zhu; Shifa Wang
Journal:  RSC Adv       Date:  2019-09-19       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.